Christoph Varenhorst

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

Lars Wallentin, Christoph Varenhorst, Stefan James et al. · European Heart Journal · 2007 · 455 citations · Full text

Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study

David Erlinge, Akiko Maehara, Ori Ben‐Yehuda et al. · The Lancet · 2021 · 423 citations

Medical Ultrasound, Engineering, Vascular Image +12

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

Christoph Varenhorst, Stefan James, David Erlinge et al. · European Heart Journal · 2009 · 263 citations · Full text

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo

David Erlinge, Christoph Varenhorst, Oscar Ö. Braun et al. · Journal of the American College of Cardiology · 2008 · 216 citations

Pharmacotherapy, Poor Responsiveness, Metabolic Syndrome +16

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Daniel Lindholm, Christoph Varenhorst, Christopher Cannon et al. · European Heart Journal · 2014 · 198 citations · Full text